DNA Damage Is a Potential Marker for TP53 Mutation in Colorectal Carcinogenesis

被引:0
作者
Scalise J.R. [1 ]
Poças R.C.G. [1 ]
Caneloi T.P. [2 ]
Lopes C.O. [2 ]
Kanno D.T. [2 ]
Marques M.G. [2 ]
Valdivia J.C.M. [2 ]
Maximo F.R. [2 ]
Pereira J.A. [3 ]
Ribeiro M.L. [1 ]
Priolli D.G. [1 ,4 ]
机构
[1] Postgraduate Programme Strictu Senso in Health Science, Sao Francisco University Medical School, Sao Paulo
[2] Scientific Initiation Student, Scientific Initiation Programme, Sao Francisco University Medical School, Sao Paulo
[3] Department of Pathology, Sao Francisco University Medical School, Sao Paulo
[4] Rua São Vicente 614. Jardim Paulista, Atibaia, CEP: 12947-390, SP
基金
巴西圣保罗研究基金会;
关键词
Adenocarcinoma; Adenoma; DNA damage; Immunohistochemistry; Tumor suppressor protein p53;
D O I
10.1007/s12029-016-9846-0
中图分类号
学科分类号
摘要
Purpose: The ability to measure oxidative DNA damage in a tissue allows establishment of the relationship between DNA damage and mutations in normal and neoplastic cells. It is well known that TP53 is a key inhibitor of tumor development and preserves the genome integrity in each cell. The aim of the present study was to investigate the relationship between DNA damage and TP53 mutation in colorectal adenoma and adenocarcinoma, and the value of DNA damage as potential marker of TP53 mutation in non-tumor tissues adjacent to colon malignant lesions. Methods: Tissue samples were obtained by colonoscopy from patients with adenoma and/or adenocarcinoma and from healthy volunteers. Diagnosis was defined by histopathology. Immunohistochemistry with computer-assisted image analysis was performed to quantify TP53 mutation. Oxidative DNA damage was determined by comet assay. Statistical analyses were performed with 5 % of significance level. Results: The TP53 level was higher in non-tumor tissues from tumor patients than in normal tissues from healthy volunteers (p = 0.01). Likewise, higher TP53 levels were observed in tumor tissues compared with the non-tumor tissues (p = 0.00). Oxidative DNA damage levels were higher in tumor tissues than in non-tumor tissues (p = 0.00). The amount of TP53 (p = 0.00) and oxidative DNA damage (p = 0.00) in normal and tumor tissue was related. The relationship between oxidative DNA damage and TP53 mutation was demonstrated in all samples (p = 0.00). Conclusion: Oxidative DNA damage is an intervening variable for TP53 mutation in colorectal adenoma-carcinoma. Our data suggests that oxidative DNA damage is a potential marker of TP53 mutation in colorectal carcinogenesis. © 2016, Springer Science+Business Media New York.
引用
收藏
页码:409 / 416
页数:7
相关论文
共 50 条
  • [41] A limited role for TP53 mutation in the transformation of follicular lymphoma to diffuse large B-cell lymphoma
    Davies, AJ
    Lee, AM
    Taylor, C
    Clear, AJ
    Goff, LK
    Iqbal, S
    Cuthbert-Heavens, D
    Calaminici, M
    Norton, AJ
    Lister, TA
    Fitzgibbon, J
    LEUKEMIA, 2005, 19 (08) : 1459 - 1465
  • [42] Significance of TP53 Mutation in Wilms Tumors with Diffuse Anaplasia: A Report from the Children's Oncology Group
    Ooms, Ariadne H. A. G.
    Gadd, Samantha
    Gerhard, Daniela S.
    Smith, Malcolm A.
    Auvil, Jaime M. Guidry
    Meerzaman, Daoud
    Chen, Qing-Rong
    Hsu, Chih Hao
    Yan, Chunhua
    Nguyen, Cu
    Hu, Ying
    Ma, Yussanne
    Zong, Zusheng
    Mungall, Andrew J.
    Moore, Richard A.
    Marra, Marco A.
    Huff, Vicki
    Dome, Jeffrey S.
    Chi, Yueh-Yun
    Tian, Jing
    Geller, James I.
    Mullighan, Charles G.
    Ma, Jing
    Wheeler, David A.
    Hampton, Oliver A.
    Walz, Amy L.
    van den Heuvel-Eibrink, Marry M.
    de Krijger, Ronald R.
    Ross, Nicole
    Gastier-Foster, JulieM.
    Perlman, Elizabeth J.
    CLINICAL CANCER RESEARCH, 2016, 22 (22) : 5582 - 5591
  • [43] Analysis of TP53 Codon 72 Polymorphism in Mucinous and Non-Mucinous Colorectal Adenocarcinoma in Isfahan, Iran
    Dastjerdi, Mehdi Nikbahkt
    IRANIAN JOURNAL OF MEDICAL SCIENCES, 2010, 35 (01) : 33 - 39
  • [44] Quantitative evaluation of TP53 immunohistochemistry to predict gene mutations: lessons learnt from a series of colorectal carcinomas
    Prall, Friedrich
    Huehns, Maja
    HUMAN PATHOLOGY, 2019, 84 : 246 - 253
  • [45] Crohn's disease-associated colorectal carcinogenesis. TP53 mutations and copy number gains of chromosome arm5p as (early) markers of tumor progression
    Hirsch, D.
    Gaiser, T.
    PATHOLOGE, 2018, 39 : 253 - 261
  • [46] Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma
    Andujar, Pascal
    Pairon, Jean-Claude
    Renier, Annie
    Descatha, Alexis
    Hysi, Ilir
    Abd-Alsamad, Issam
    Billon-Galland, Marie-Annick
    Blons, Helene
    Clin, Benedicte
    Danel, Claire
    Debrosse, Denis
    Galateau-Salle, Francoise
    Housset, Bruno
    Laurent-Puig, Pierre
    Le Pimpec-Barthes, Francoise
    Letourneux, Marc
    Monnet, Isabelle
    Regnard, Jean-Francois
    Validire, Pierre
    Zucman-Rossi, Jessica
    Jaurand, Marie-Claude
    Jean, Didier
    MUTAGENESIS, 2013, 28 (03) : 323 - 331
  • [47] A Novel TP53 Mutation Associated with TWIST1 and SIP1 Expression in an Aggressive Adrenocortical Carcinoma
    Bulzico, Daniel
    Torres, Davi Coe
    Ferreira, Gerson Moura
    Barreto Pires, Bruno Ricardo
    Silvestre de Faria, Paulo Antonio
    Hassan, Rocio
    Abdelhay, Eliana
    Vaisman, Mario
    Vieira Neto, Leonardo
    ENDOCRINE PATHOLOGY, 2017, 28 (04) : 326 - 331
  • [48] Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53 mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencing analysis
    Yemelyanova, Anna
    Vang, Russell
    Kshirsagar, Malti
    Lu, Dan
    Marks, Morgan A.
    Shih, Ie Ming
    Kurman, Robert J.
    MODERN PATHOLOGY, 2011, 24 (09) : 1248 - 1253
  • [49] A proposal for the integration of immunohistochemical staining and DNA-based techniques for the determination of TP53 mutations in human carcinomas
    Logullo, AF
    de Moura, RP
    Nonogaki, S
    Kowalski, LP
    Nagai, MA
    Simpson, AJG
    DIAGNOSTIC MOLECULAR PATHOLOGY, 2000, 9 (01) : 35 - 40
  • [50] Immunohistochemical Expression of CDX2, β-Catenin, and TP53 in Inflammatory Bowel Disease-associated Colorectal Cancer
    Laurent, Camille
    Svrcek, Magali
    Flejou, Jean-Francois
    Chenard, Marie-Pierre
    Duclos, Bernard
    Freund, Jean-Noel
    Reimund, Jean-Marie
    INFLAMMATORY BOWEL DISEASES, 2011, 17 (01) : 232 - 240